Distinguished in Malignant Mixed Mullerian Tumor

Dr. Stephanie L. Gaillard

Oncology
Johns Hopkins University
5759 Cedar Ln, 
Columbia, MD 
Accepting New Patients
Offers Telehealth
Distinguished in Malignant Mixed Mullerian Tumor
Johns Hopkins University
5759 Cedar Ln, 
Columbia, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Stephanie Gaillard is an Oncologist in Columbia, Maryland. Dr. Gaillard is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Tissue Biopsy, and Salpingo-Oophorectomy. Dr. Gaillard is currently accepting new patients.

Her clinical research consists of co-authoring 69 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in MD
Hospital Affiliations
Sibley Memorial Hospital
The Johns Hopkins Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

JOHNS HOPKINS UNIVERSITY
5759 Cedar Ln, Columbia, MD 21044
Other Locations
JOHNS HOPKINS UNIVERSITY
600 N Wolfe St, Blalock 266, Baltimore, MD 21287
JOHNS HOPKINS UNIVERSITY
5755 Cedar Ln, Columbia, MD 21044
JOHNS HOPKINS UNIVERSITY
10803 Falls Rd, Lutherville, MD 21093

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
Phase 1a/1b Open Label Dose-escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Phase 1a/1b Open Label Dose-escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Enrollment Status: Completed
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drug: TPST-1495
Study Phase: Phase 1
A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cabozantinib S-malate, Nivolumab
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Other, Biological
Study Drug: Vigil
Study Phase: Phase 2
A Pilot Clinical Trial Assessing the Safety and Feasibility of Intramuscular Administration of the TA-CIN Vaccine as Adjuvant Therapy for Patients With History of HPV16 Associated Cervical Cancer
A Pilot Clinical Trial Assessing the Safety and Feasibility of Intramuscular Administration of the TA-CIN Vaccine as Adjuvant Therapy for Patients With History of HPV16 Associated Cervical Cancer
Enrollment Status: Completed
Publish Date: March 04, 2025
Intervention Type: Biological
Study Drug: Tissue Antigen - Cervical Intraepithelial Neoplasia Vaccine
Study Phase: Phase 1
An Open-Label, Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma
An Open-Label, Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma
Enrollment Status: Approved_for_marketing
Publish Date: December 16, 2024
Intervention Type: Drug
Phase I Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Phase I Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Enrollment Status: Completed
Publish Date: October 24, 2024
Intervention Type: Drug
Study Drugs: Fostamatinib, Paclitaxel
Study Phase: Phase 1
A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Pilot Study Investigating the Effect of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers of Mullerian Origin
A Pilot Study Investigating the Effect of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers of Mullerian Origin
Enrollment Status: Completed
Publish Date: February 21, 2024
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Early Phase 1
A Feasibility Trial to Assess Intratumoral Injection of TA-CIN With Anti-PD-1 Therapy for Recurrent HPV16-associated Cancers
A Feasibility Trial to Assess Intratumoral Injection of TA-CIN With Anti-PD-1 Therapy for Recurrent HPV16-associated Cancers
Enrollment Status: Withdrawn
Publish Date: December 01, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
Enrollment Status: Terminated
Publish Date: September 10, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic Cancers
A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic Cancers
Enrollment Status: Completed
Publish Date: February 11, 2022
Atezolizumab in Combination With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery for Patients With Newly-Diagnosed Advanced-Stage Epithelial Ovarian Cancer
Atezolizumab in Combination With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery for Patients With Newly-Diagnosed Advanced-Stage Epithelial Ovarian Cancer
Enrollment Status: Completed
Publish Date: August 12, 2021
Intervention Type: Drug
Study Drugs: Atezolizumab, Carboplatin, Paclitaxel, Bevacizumab
Study Phase: Phase 1/Phase 2
Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Enrollment Status: Completed
Publish Date: October 16, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 15 Less Clinical Trials

69 Total Publications

Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clinical practice statement.
Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clinical practice statement.
Journal: Gynecologic oncology
Published: August 12, 2025
Similar Doctors
Distinguished in Malignant Mixed Mullerian Tumor
Dr. Charles R. Boice
Gynecologic Oncology | Oncology
Distinguished in Malignant Mixed Mullerian Tumor
Dr. Charles R. Boice
Gynecologic Oncology | Oncology

Medstar Medical Group Ii LLC

1406 Crain S Hwy 106, 
Glen Burnie, MD 
 (14.3 miles away)
410-768-6440
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Charles Boice is a Gynecologic Oncologist and an Oncologist in Glen Burnie, Maryland. Dr. Boice is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. His top areas of expertise are Neuroendocrine Carcinoma of the Cervix, Cervical Cancer, Malignant Mixed Mullerian Tumor, Hernia Surgery, and Oophorectomy. Dr. Boice is currently accepting new patients.

Distinguished in Malignant Mixed Mullerian Tumor
Dr. Annette Bicher
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Malignant Mixed Mullerian Tumor
Dr. Annette Bicher
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Capital Womens Care LLC

2301 Research Blvd, Suite 215, 
Rockville, MD 
 (17.7 miles away)
301-424-3444
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Annette Bicher is a Gynecologic Oncologist and an Oncologist in Rockville, Maryland. Dr. Bicher is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. Her top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Ovarian Carcinosarcoma, Hernia Surgery, and Ureteroscopy. Dr. Bicher is currently accepting new patients.

Distinguished in Malignant Mixed Mullerian Tumor
Dr. Dwight D. Im
Gynecologic Oncology | Oncology
Distinguished in Malignant Mixed Mullerian Tumor
Dr. Dwight D. Im
Gynecologic Oncology | Oncology

St Paul Place Specialists Inc

7602 Belair Rd, 
Baltimore, MD 
 (22.3 miles away)
410-663-8100
Languages Spoken:
English, Korean
See accepted insurances
Accepting New Patients

Dwight Im is a Gynecologic Oncologist and an Oncologist in Baltimore, Maryland. Dr. Im is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. His top areas of expertise are Rectocele, Endometrial Cancer, Endometrial Stromal Sarcoma, Hysterectomy, and Oophorectomy. Dr. Im is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gaillard's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 8 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile